<DOC>
	<DOCNO>NCT00310843</DOCNO>
	<brief_summary>Attempt identify genetic polymorphism interrogate pathway may associate symptomatic hepatotoxicity severe cutaneous toxicity observe case patient within first 8 week nevirapine therapy .</brief_summary>
	<brief_title>Case-Control Viramune ( Nevirapine ) Toxicogenomics Study</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion Case 1 . Male female patient &gt; =18 year age HIV1 infection experience one follow adverse reaction within first 8 week start nevirapine therapy : Grade 3 4 LFT elevation ( ALT AST &gt; 5X ULN ) symptom consistent clinical hepatitis ( see Appendix 10.1 ) Acute liver failure secondary nevirapine therapy* Functional group III IV rash *Acute liver failure define serious liver injury usually require hospitalization may lead death liver transplantation . Inclusion Control 2 . Male female patient &gt; =18 year age HIV1 infection expose nevirapine therapy least 18 week meet case inclusion criterion Exclusion Cases 1 . Patients hepatotoxicity rash event investigator judgement relate nevirapine use ( ex . hepatotoxicity due alcohol medicinal use rash due medicinal use ) . 2 . Patients begin abacavir TMPSMX ( trimethoprim/sulfamethoxazole ) therapy 2 week less prior 8 week initiate nevirapine therapy . 3 . Patients AST ALT elevation &gt; 5 time ULN ( &gt; = Grade 3 ) prior initiation nevirapine therapy . Exclusion Controls 4 . Patients discontinued nevirapine complete 18 week dose 200 mg/day 2 week follow 400 mg/day thereafter . 5 . Patients develop functional group I , IIa IIb rash within 18 week start nevirapine therapy , dermatologic condition could plausibly attribute nevirapine . 6 . Patients ALT AST elevation &gt; 2.5 X ULN ( &gt; Grade 1 ) within 18 week start nevirapine therapy . 7 . Any hepatobiliary adverse event could possibly attribute nevirapine . 8 . Patients develop systemic reaction attributable nevirapine use first 18 week nevirapine treatment flulike symptom , arthralgia , myalgia , conjunctivitis . Exclusion Cases Controls 9 . Patients participate 2NNLongterm Followup study ( 1100.1454 ) 10 . Patients CD4 count 150 cells/mm3 prior initiation nevirapine therapy ( last available result measure 6 month prior initiation nevirapine therapy ) . 11 . Evidence acute coinfection viral hepatitis . 12 . Patients take prednisone , prednisolone , immunomodulatory medication within first 8 week nevirapine therapy . 13 . Patients unwilling provide blood sample DNA test . 14 . Patients sign inform consent authorization release protect health information per local requirement . 15 . Patients without available liv</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>